<DOC>
	<DOCNO>NCT03000569</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics efficacy SAGE-217 30 subject Parkinson 's Disease Moderate Severity .</brief_summary>
	<brief_title>A Study Evaluate SAGE-217 Patients With Parkinson 's Disease Moderate Severity</brief_title>
	<detailed_description>Part A study open-label design dose Levodopa 3 day follow SAGE-217 4 day . Part B study randomize , placebo-controlled , two-sequence crossover design . Eligible subject randomize open-label Levodopa plus blind SAGE-217 placebo Period 1 ( 4 day ) . In Period 2 ( 4 day ) subject receive open-label SAGE-217 4 day .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Subject diagnosis idiopathic Parkinson 's Disease ( Hoehn Yahr Stage 2 Stage 3 ) duration le 7 year prior screen Subject stable dose ( least 1 month prior baseline visit ) antiparkinsonian agent include immediaterelease oral Levodopa CarbidopaLevodopa willing remain dose duration study Subject early ( Hoehn Yahr Stage 1 ) advance ( Hoehn Yahr Stage 4 Stage 5 ) Parkinson 's Disease Subject presence druginduced parkinsonism , metabolic identify neurogenetic disorder , encephalitis , atypical Parkinsonian syndromes Medical history electroconvulsive therapy stereotaxic brain surgery Parkinson 's Disease Medical history suicide attempt within 2 year screen current suicidal ideation Medical history impulse control disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson</keyword>
</DOC>